# Acceptance of a third COVID-19 vaccine dose, vaccine interchangeability, and clinical trial enrolment among parents of children 12–17 years in Lima, Perú

**Authors:** Carlos R. Celis, Lucie Ecker, Giancarlo Alvarado-Gamarra, Katherine Alcalá-Marcos, Noé Atamari-Anahui, Maria Pia Balmaceda, Kevin Florian, Rodrigo Paredes de la Fuente, Leigh M. Howard, Carlos G. Grijalva, Claudio F. Lanata

PMC · DOI: 10.3389/fpubh.2024.1421746 · Frontiers in Public Health · 2024-08-14

## TL;DR

This study explores how parents in Lima, Peru feel about giving their children a third COVID-19 vaccine dose, allowing them to join vaccine trials, and using different vaccine brands.

## Contribution

The study identifies factors influencing parental acceptance of third vaccine doses and clinical trial participation in Peru.

## Key findings

- Most parents (90.4%) would accept a third vaccine dose for their children.
- Approximately a third (36.6%) would allow their children to join a vaccine trial.
- Belief in vaccine study quality was strongly linked to acceptance of vaccine-related outcomes.

## Abstract

To characterize factors associated with parental willingness for their children participation in a COVID-19 vaccine trial, use of different COVID-19 vaccines and acceptance of a third vaccine dose.

Parents of children aged 12–17 years in Lima, Perú were asked to complete an online questionnaire via social networks, from November 9, 2021, to April 23, 2022. We calculated crude and adjusted prevalence ratios with 95% confidence intervals to compare factors with the mentioned outcomes.

From 523 parents responding, 374 completed the survey. 90.4% would give their children a third vaccine dose, 36.6% would allow their children participation in a COVID-19 vaccine clinical trial, and 33.2% would accept different vaccine brands between doses. Parental belief that COVID-19 vaccine studies met quality standards was associated with acceptance of a third booster dose (adjusted PR 3.25; 95% CI1.57–6.74; p = 0.002), enrolment in a COVID-19 clinical trial (adjusted PR 4.49; 95% CI1.25–16.06; p = 0.02), and acceptance of different COVID-19 vaccine brands between doses (adjusted PR 10.02; 95% CI1.40–71.95; p = 0.02).

Most parents would accept a third vaccine booster dose, approximately a third would participate in COVID-19 vaccine trials. Believing COVID-19 vaccines studies fulfilled quality standards was associated with the study outcomes. It is necessary to inform about the rigorous processes for the development of COVID-19 vaccines to generate confidence in parents to accept these vaccine-related outcomes.

## Linked entities

- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** COVID-19 (MESH:D000086382)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11349562/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC11349562/full.md

---
Source: https://tomesphere.com/paper/PMC11349562